Bionter

About Bionter

The startup develops analytical testing devices that utilize combination light obscuration technology for sub-visible particle testing, which is essential for ensuring patient safety in parenteral preparations. Their services support stability testing, drug formulation, and in-process control during manufacturing, enabling clients to meet regulatory requirements and enhance product quality.

<problem> Parenteral preparations require rigorous sub-visible particle testing to ensure patient safety and meet stringent regulatory requirements. Traditional analytical testing methods can be limited in their ability to accurately and efficiently detect and characterize these particles, impacting drug formulation, stability testing, and in-process control during manufacturing. </problem> <solution> The startup provides analytical testing devices leveraging combination light obscuration (LO) technology for precise sub-visible particle analysis. Their devices enable comprehensive characterization of particulate matter in parenteral preparations, supporting enhanced product quality and patient safety. By offering advanced analytical capabilities, the startup empowers pharmaceutical manufacturers to optimize drug formulation, conduct thorough stability testing, and maintain robust in-process control throughout the manufacturing lifecycle. This technology ensures compliance with regulatory standards and facilitates the development of safe and effective injectable medications. </solution> <features> - Combination light obscuration technology for accurate sub-visible particle detection and sizing - Automated particle counting and characterization - Real-time data analysis and reporting - Compliance with USP <788> and other relevant regulatory guidelines - Integrated software for data management and audit trails </features> <target_audience> The primary customers are pharmaceutical manufacturers, compounding pharmacies, and research laboratories involved in the development, production, and quality control of parenteral drug products. </target_audience>

What does Bionter do?

The startup develops analytical testing devices that utilize combination light obscuration technology for sub-visible particle testing, which is essential for ensuring patient safety in parenteral preparations. Their services support stability testing, drug formulation, and in-process control during manufacturing, enabling clients to meet regulatory requirements and enhance product quality.

Where is Bionter located?

Bionter is based in Riehen, Switzerland.

How much funding has Bionter raised?

Bionter has raised 3850000.

Location
Riehen, Switzerland
Funding
3850000
Employees
4 employees
Major Investors
Dynamk Capital

Find Investable Startups and Competitors

Search thousands of startups using natural language

Bionter

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

The startup develops analytical testing devices that utilize combination light obscuration technology for sub-visible particle testing, which is essential for ensuring patient safety in parenteral preparations. Their services support stability testing, drug formulation, and in-process control during manufacturing, enabling clients to meet regulatory requirements and enhance product quality.

bionter.com1K+
cb
Crunchbase
Riehen, Switzerland

Funding

$

Estimated Funding

$3M+

Major Investors

Dynamk Capital

Team (<5)

No team information available.

Company Description

Problem

Parenteral preparations require rigorous sub-visible particle testing to ensure patient safety and meet stringent regulatory requirements. Traditional analytical testing methods can be limited in their ability to accurately and efficiently detect and characterize these particles, impacting drug formulation, stability testing, and in-process control during manufacturing.

Solution

The startup provides analytical testing devices leveraging combination light obscuration (LO) technology for precise sub-visible particle analysis. Their devices enable comprehensive characterization of particulate matter in parenteral preparations, supporting enhanced product quality and patient safety. By offering advanced analytical capabilities, the startup empowers pharmaceutical manufacturers to optimize drug formulation, conduct thorough stability testing, and maintain robust in-process control throughout the manufacturing lifecycle. This technology ensures compliance with regulatory standards and facilitates the development of safe and effective injectable medications.

Features

Combination light obscuration technology for accurate sub-visible particle detection and sizing

Automated particle counting and characterization

Real-time data analysis and reporting

Compliance with USP <788> and other relevant regulatory guidelines

Integrated software for data management and audit trails

Target Audience

The primary customers are pharmaceutical manufacturers, compounding pharmacies, and research laboratories involved in the development, production, and quality control of parenteral drug products.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.